Select Equity Group L.P. Sells 1,491,749 Shares of Enovis Co. (NYSE:ENOV)

Select Equity Group L.P. lessened its stake in shares of Enovis Co. (NYSE:ENOV) by 72.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 556,638 shares of the company’s stock after selling 1,491,749 shares during the quarter. Select Equity Group L.P.’s holdings in Enovis were worth $25,160,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. American Century Companies Inc. boosted its holdings in Enovis by 78.6% in the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock valued at $68,337,000 after purchasing an additional 665,208 shares during the period. Magnetar Financial LLC boosted its stake in shares of Enovis by 66.7% in the second quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after buying an additional 442,051 shares during the period. Diamond Hill Capital Management Inc. increased its stake in Enovis by 14.5% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock worth $125,929,000 after acquiring an additional 352,116 shares during the period. UBS Group AG raised its holdings in Enovis by 1,060.8% in the 4th quarter. UBS Group AG now owns 333,510 shares of the company’s stock valued at $18,683,000 after acquiring an additional 304,779 shares in the last quarter. Finally, Boston Partners lifted its position in shares of Enovis by 206.5% during the 1st quarter. Boston Partners now owns 295,969 shares of the company’s stock valued at $18,455,000 after acquiring an additional 199,411 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Up 2.3 %

ENOV opened at $43.39 on Friday. The company’s 50 day moving average is $44.48 and its 200-day moving average is $49.52. The company has a market cap of $2.42 billion, a P/E ratio of -28.93 and a beta of 1.92. The company has a current ratio of 2.26, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Enovis Co. has a 1-year low of $39.98 and a 1-year high of $65.03.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The business had revenue of $525.20 million during the quarter, compared to analyst estimates of $525.99 million. During the same quarter last year, the business earned $0.61 EPS. The firm’s quarterly revenue was up 22.6% on a year-over-year basis. Equities research analysts predict that Enovis Co. will post 2.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of a number of recent analyst reports. Evercore ISI decreased their price target on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Needham & Company LLC dropped their target price on shares of Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $69.13.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.